US2019292242A1PendingUtilityA1

Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof

Assignee: ALKAYALI AHMADPriority: Feb 22, 2017Filed: Apr 2, 2019Published: Sep 26, 2019
Est. expiryFeb 22, 2037(~10.6 yrs left)· nominal 20-yr term from priority
Inventors:Ahmad Alkayali
A61P 39/00A61P 39/06A61P 9/14A61P 25/28A61P 29/00A61P 17/00A61P 19/02A61P 25/00A61K 8/65A61Q 19/00A23L 2/00A61Q 19/08A61K 38/014C07K 14/78A61K 38/00A61K 35/614C12P 21/06A61K 8/00
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Hydrolyzed collagen types I, II, and V powder compositions, method of preparing the compositions, and use of the compositions in treating a variety of ailments. The compositions are topically or orally administered to an individual at a daily dosage between 1500 mg and 2000 mg.

Claims

exact text as granted — not AI-modified
I claim: 
     
         1 . A method of providing collagen type I, collagen type II, and collagen type V as a supplement comprising:
 a. administering to an individual an effective daily dose of a jellyfish derived material, and wherein the jellyfish derived material comprises hydrolyzed collagen type I, hydrolyzed collagen type II, and hydrolyzed collagen type V.   
     
     
         2 . The method of  claim 1  wherein the jellyfish-derived material derived from a group of jellyfish species comprising  Stomolophus meleagris  and  Acromitus hardenbergi.    
     
     
         3 . The method of  claim 1  wherein each of the hydrolyzed collagen type I, hydrolyzed collagen type II, and hydrolyzed collagen type V have an average molecular weight between 4 kilodaltons and 20 kilodaltons. 
     
     
         4 . The method of  claim 3  wherein each of the hydrolyzed collagen type I, hydrolyzed collagen type II, and Hydrolyzed collagen type V have an average molecular weight between 15 kilodaltons and 20 kilodaltons. 
     
     
         5 . The method of  claim 1 , wherein the supplement is administered and formulated as a topical cream. 
     
     
         6 . The method of  claim 5 , wherein the topical cream prevents an ailment comprising; neurodegenerative disease, degenerative joint diseases, joint defects, osteoarthritis, vascular disease, fatigue, cell oxidation, photo-aging, skin conditions, calcium binding proteins, memory loss, and decreased brain function. 
     
     
         7 . The method of  claim 5 , wherein an effective daily amount is between 200 mg and 5000 mg. 
     
     
         8 . The method of  claim 5 , wherein the effective daily amount is between 1500 mg and 2000 mg. 
     
     
         9 . The method of  claim 1  wherein the supplement is orally administered. 
     
     
         10 . The method of  claim 9 , wherein the orally administered supplement is a formulation comprising; one or more gelatin capsules, one or more aqueous suspensions, one or more oil suspensions, one or more elixirs, one or more tablets, and a powder. 
     
     
         11 . The method of  claim 10 , wherein the orally administered supplement prevents an ailment comprising; neurodegenerative disease, degenerative joint diseases, joint defects, osteoarthritis, vascular disease, fatigue, cell oxidation, photo-aging, skin conditions, calcium binding proteins, memory loss, and decreased brain function. 
     
     
         12 . The method of  claim 10 , wherein the effective daily does is between 200 mg and 5000 mg. 
     
     
         13 . The method of  claim 10 , wherein the effective daily does is between 1500 mg and 2000 mg.

Join the waitlist — get patent alerts

Track US2019292242A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.